Abstract
Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER ≥50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 654-660 |
| Number of pages | 7 |
| Journal | Breast |
| Volume | 17 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2008 |
Fingerprint
Keywords
- Breast cancer
- Chemoendocrine therapy
- Predictive factors
- Primary therapy
ASJC Scopus subject areas
- Surgery
Cite this
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. / Torrisi, Rosalba; Dellapasqua, Silvia; Ghisini, Raffaella; Viale, Giuseppe; Veronesi, Paolo; Luini, Alberto; Intra, Mattia; Peruzzotti, Giulia; Rocca, Andrea; Balduzzi, Alessandra; Cardillo, Anna; Goldhirsch, Aron; Colleoni, Marco.
In: Breast, Vol. 17, No. 6, 12.2008, p. 654-660.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
AU - Torrisi, Rosalba
AU - Dellapasqua, Silvia
AU - Ghisini, Raffaella
AU - Viale, Giuseppe
AU - Veronesi, Paolo
AU - Luini, Alberto
AU - Intra, Mattia
AU - Peruzzotti, Giulia
AU - Rocca, Andrea
AU - Balduzzi, Alessandra
AU - Cardillo, Anna
AU - Goldhirsch, Aron
AU - Colleoni, Marco
PY - 2008/12
Y1 - 2008/12
N2 - Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER ≥50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.
AB - Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER ≥50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.
KW - Breast cancer
KW - Chemoendocrine therapy
KW - Predictive factors
KW - Primary therapy
UR - http://www.scopus.com/inward/record.url?scp=56649102283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649102283&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2008.05.002
DO - 10.1016/j.breast.2008.05.002
M3 - Article
C2 - 18595702
AN - SCOPUS:56649102283
VL - 17
SP - 654
EP - 660
JO - Breast
JF - Breast
SN - 0960-9776
IS - 6
ER -